590 related articles for article (PubMed ID: 30523328)
21. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
[TBL] [Abstract][Full Text] [Related]
22. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.
Croucher DC; Richards LM; Tsofack SP; Waller D; Li Z; Wei EN; Huang XF; Chesi M; Bergsagel PL; Sebag M; Pugh TJ; Trudel S
Nat Commun; 2021 Nov; 12(1):6322. PubMed ID: 34732728
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B; Corchete LA; Vidriales MB; Puig N; Maiso P; Rodriguez I; Alignani D; Burgos L; Sanchez ML; Barcena P; Echeveste MA; Hernandez MT; García-Sanz R; Ocio EM; Oriol A; Gironella M; Palomera L; De Arriba F; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Lahuerta JJ; Blade J; Orfao A; Mateos MV; San Miguel JF;
Blood; 2016 Apr; 127(15):1896-906. PubMed ID: 26755711
[TBL] [Abstract][Full Text] [Related]
25. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
[TBL] [Abstract][Full Text] [Related]
26. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
27. The genetic architecture of multiple myeloma.
Morgan GJ; Walker BA; Davies FE
Nat Rev Cancer; 2012 Apr; 12(5):335-48. PubMed ID: 22495321
[TBL] [Abstract][Full Text] [Related]
28. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
Bustoros M; Anand S; Sklavenitis-Pistofidis R; Redd R; Boyle EM; Zhitomirsky B; Dunford AJ; Tai YT; Chavda SJ; Boehner C; Neuse CJ; Rahmat M; Dutta A; Casneuf T; Verona R; Kastritis E; Trippa L; Stewart C; Walker BA; Davies FE; Dimopoulos MA; Bergsagel PL; Yong K; Morgan GJ; Aguet F; Getz G; Ghobrial IM
Nat Commun; 2022 Jun; 13(1):3449. PubMed ID: 35705541
[TBL] [Abstract][Full Text] [Related]
29. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo PY; Keats J; DeRome M; Yesil J; Auclair D; Lonial S; Chari A; Cho HJ; Barlogie B; Jagannath S; Dudley JT; Parekh S
Leukemia; 2018 Jan; 32(1):120-130. PubMed ID: 28642592
[TBL] [Abstract][Full Text] [Related]
30. Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
[TBL] [Abstract][Full Text] [Related]
31. Co-evolution of tumor and immune cells during progression of multiple myeloma.
Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
[TBL] [Abstract][Full Text] [Related]
32. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T; Schoebe N; Mai S
Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow eosinophils in plasma cell disorders.
Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
Exp Hematol; 2018 Oct; 66():27-31.e5. PubMed ID: 29981782
[TBL] [Abstract][Full Text] [Related]
34. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum.
Tapia-Alveal C; Olsen TR; Worgall TS
Commun Biol; 2020 Dec; 3(1):781. PubMed ID: 33335255
[TBL] [Abstract][Full Text] [Related]
35. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
Treon SP; Maimonis P; Bua D; Young G; Raje N; Mollick J; Chauhan D; Tai YT; Hideshima T; Shima Y; Hilgers J; von Mensdorff-Pouilly S; Belch AR; Pilarski LM; Anderson KC
Blood; 2000 Nov; 96(9):3147-53. PubMed ID: 11049996
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
37. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
38. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA
Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579
[TBL] [Abstract][Full Text] [Related]
39. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?
Tatsas AD; Jagasia MH; Chen H; McCurley TL
Am J Clin Pathol; 2010 Jul; 134(1):139-44. PubMed ID: 20551278
[TBL] [Abstract][Full Text] [Related]
40. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
